A Major Step Toward Precision Medicine for Malignant Brain Tumors

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)

Purpose of Study

The study is an adaptive randomization trial in which multiple drugs and combinations of drugs are screened simultaneously and over time. Unlike most clinical trials, this study can be modified based on the results and information obtained from participants and therapies can be redefined in each individual patient as the trial goes on.

Who Can Participate?

Patients 18 years or older who have been newly diagnosed with glioblastoma (GBM) or recurrent GBM may be eligible to participate in the study.

Study ID

• GCAR1319
• NCT03970447